London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
LifeSciences division The Overnight Service for DNA sequencing has enabled the Group to further increase its share of the UK market. Sequencing volumes during Q3 were 27% greater than the same period last year and 46% up on a year to date basis. This enhanced service has also enabled the Group to win sequencing tenders from the Universities of Warwick and Newcastle. In July we announced an extended next generation sequencing service using the new Illumina MiSeq™ platform. This platform addresses the "middle ground" between the Group's existing sequencing technologies and has already attracted customers from both the life science research and healthcare communities. GenomeCube®, our proprietary search engine and bioinformatics tool for our clone and antibody portfolio, has enabled the appointment of additional distributors, extending the global reach of our products business. In August we announced the appointment of a third distributor in the important South East Asia market, Benebiosis of South Korea, and in the period we appointed a fourth distributor in the region, Michrom of Malaysia. During the period we further enhanced our network in Europe with additional distributors appointed in Turkey, Italy and Poland.
INTERIM MANAGEMENT STATEMENT Source BioScience plc (LSE: SBS), the international diagnostics and genetic analysis business serving the healthcare and research markets today publishes its Interim Management Statement for the period from 1 July 2012 to 14 November 2012. Unless otherwise stated, the financial information referenced below refers to the three months ended 30 September 2012, and the corresponding period last year, this being the latest practicable date to which financial information has been prepared. Overall business performance The third quarter of 2012 has been another period of sustained growth and development for Source BioScience with increased revenue in both the LifeSciences and Healthcare divisions, compared with the same period last year. This performance has been underpinned by growth in the Cytology business, driven by the adoption of automated imaging for cervical cancer screening, coupled with increasing market share for DNA sequencing in the UK. The Group remains in a robust financial position with £2.0 million cash at the end of September 2012 (30 June 2012: £1.8 million). Overall performance for the year to date is in line with management's expectations, representing a continuation of the strong business performance achieved last year. We expect full year profits to be in line with market expectations.
usually means someone buying big ,in company like this
Things definitely happening here - good company going somewhere even better. JUNGLE RUMBLE
Hi All new to this share, any long time holders want to give a view to the future
this is a great company ,well run and a good take over prospect for all the data they have ,can only go up from now
Thank's for that :-)
It is. I recieved an email from Galvan with a report on Source Bio by Faraday Research (sister company) tipping this share.
"You see this innovative company – based in Nottingham - is Europe’s leading provider of DNA sequencing and bioinformatics. Put simply, it owns a vast ‘bio-bank’ of data. With over 20 million DNA clones and over 100,000 antibodies, this small company could be sitting on a ‘medical goldmine’."
does anyone else rate these shares
long way to go up .really undervalued
looks like i might have called this one right
just waiting to take off ,great company extremely underrated
in the ranks. Up to average daily volume by 9:15.
real shame the management are not getting the value of the company it deserves ,well run company and well under valued , surprised not been a takeover target
I see you are even here, was in SBS a while ago. It's a very good company but somewhat unloved stock, not sure I would risk coming back...
impressive results siso29 ,regret selling lol
im not management and todays figures prove solid and well run company ,continues to get better and company is saving lives ,and many top institutions are buying in very strong buy
tombi 1 is clearly the management. don't believe it. get out while you can!